Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia, Blut, vol.53, issue.6, pp.423-459, 1986. ,
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol ESMO, vol.25, issue.3, pp.57-69, 2014. ,
Myelodysplastic syndromes, Lancet Lond Engl, vol.383, issue.9936, pp.2239-52, 2014. ,
Therapy-related leukemia and myelodysplasia: susceptibility and incidence, Haematologica, vol.92, issue.10, pp.1389-98, 2007. ,
Therapy-related myelodysplasia and acute myeloid leukemia, Semin Oncol, vol.40, issue.6, pp.666-75, 2013. ,
Historical perspectives on myelodysplastic syndromes, Leuk Res, vol.36, issue.12, pp.1441-52, 2012. ,
Refractory anemia: Analysis of one hundred cases, J Am Med Assoc, vol.110, issue.11, pp.794-800, 1938. ,
The hematologie syndrome preceding acute leukemia, Am J Med, vol.55, issue.1, pp.38-48, 1973. ,
Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group, Br J Haematol, vol.33, issue.4, pp.451-459, 1976. ,
The inflammatory microenvironment in MDS, Cell Mol Life Sci CMLS, vol.72, issue.10, pp.1959-66, 2015. ,
Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system, Haematologica, vol.96, issue.7, pp.1041-1049, 2011. ,
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia, Nature, vol.464, issue.7290, pp.852-859, 2010. ,
Induction of myelodysplasia by myeloid-derived suppressor cells, J Clin Invest, vol.123, issue.11, pp.4595-611, 2013. ,
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors, Blood, vol.108, issue.13, pp.4170-4177, 2006. ,
Tumor necrosis factor-? blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation, Immunity, vol.38, issue.3, pp.541-54, 2013. ,
Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab, Semin Hematol, vol.49, issue.4, pp.304-315, 2012. ,
Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes, Leukemia, vol.20, issue.3, pp.463-70, 2006. ,
Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?, Eur J Haematol, vol.88, issue.5, pp.380-387, 2012. ,
Maladies systémiques au cours des syndromes myélodysplasiques. Rev Médecine Interne, vol.16, pp.897-904, 1995. ,
Infections in myelodysplastic syndromes, Haematologica, vol.97, issue.10, pp.1459-70, 2012. ,
IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome, Br J Haematol, vol.145, issue.1, pp.64-72, 2009. ,
Immune dysregulation in myelodysplastic syndrome. Hematol Rep, vol.2, p.1, 2010. ,
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood, vol.110, pp.847-50, 2007. ,
Relapsing polychondritis and myelodysplasia: a report of two cases and review of the current literature, Clin Lab Haematol, vol.22, issue.1, pp.45-53, 2000. ,
Association between myelodysplastic syndromes and inflammatory bowel diseases, Leukemia, vol.11, issue.12, pp.2188-91, 1997. ,
Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles, Br J Haematol, vol.102, issue.5, pp.1314-1336, 1998. ,
Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression, Blood, vol.100, issue.10, pp.3639-3684, 2002. ,
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome, Blood, vol.100, issue.5, pp.1570-1574, 2002. ,
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes, Blood, vol.89, issue.6, pp.2079-88, 1997. ,
Revised international prognostic scoring system for myelodysplastic syndromes, Blood, vol.120, issue.12, pp.2454-65, 2012. ,
Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases, Leuk Res, vol.35, issue.7, pp.863-870, 2011. ,
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients, Blood, vol.110, issue.13, pp.4385-95, 2007. ,
Molecular biology of myelodysplastic syndromes, Semin Oncol, vol.38, issue.5, pp.613-633, 2011. ,
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion, Genes Chromosomes Cancer, vol.51, issue.12, pp.1086-92, 2012. ,
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine, Leuk Res, vol.38, issue.7, pp.751-756, 2014. ,
ETV6 mutations and loss in AML-M0, Leukemia, vol.22, issue.8, pp.1639-1682, 2008. ,
Clinical effect of point mutations in myelodysplastic syndromes, N Engl J Med, vol.364, issue.26, pp.2496-506, 2011. ,
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia, Br J Haematol, vol.145, issue.6, pp.788-800, 2009. ,
Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias, BMC Cancer, vol.10, p.401, 2010. ,
Epigenetics of myelodysplastic syndromes, Leukemia, vol.28, issue.3, pp.497-506, 2014. ,
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients, Blood, vol.124, issue.17, pp.2705-2717, 2014. ,
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias, Leukemia, vol.25, issue.7, pp.1147-52, 2011. ,
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders, Blood, vol.122, issue.18, pp.3169-77, 2013. ,
Frequent pathway mutations of splicing machinery in myelodysplasia, Nature, vol.478, issue.7367, pp.64-73, 2011. ,
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes, Blood, vol.119, issue.14, pp.3211-3219, 2012. ,
Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations, Blood, vol.84, issue.4, pp.1243-1251, 1994. ,
Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes, Leuk Res, vol.37, issue.3, pp.312-321, 2013. ,
Consensus français sur les syndromes myélodysplasiques (SMD) et la leucémie myélomonocytaire chronique : diagnostic, classifications, traitement. GFM, 2015. ,
The genetic basis of myelodysplasia and its clinical relevance. Blood, vol.122, pp.4021-4055, 2013. ,
, CCM : Connaitre & Combattre les Myelodysplasies, 2015.
, , 2009.
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet, Blood, vol.122, issue.17, pp.2943-64, 2013. ,
Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS, Leuk Res, vol.36, issue.1, pp.1-5, 2012. ,
Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics, Haematologica, vol.98, issue.2, pp.201-208, 2013. ,
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study, Haematologica, vol.94, issue.8, pp.1066-74, 2009. ,
Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms, Haematologica, vol.100, issue.4, pp.472-480, 2015. ,
Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes, Leukemia, vol.27, issue.10, pp.1981-1988, 2013. ,
Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation, Blood, vol.102, issue.1, pp.394-403, 2003. ,
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.30, issue.5, pp.937-51, 2009. ,
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, issue.20, pp.2391-405, 2016. ,
Proposals for the classification of the myelodysplastic syndromes, Br J Haematol, vol.51, issue.2, pp.189-99, 1982. ,
The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, vol.100, issue.7, pp.2292-302, 2002. ,
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial, Haematologica, vol.98, issue.7, pp.1067-72, 2013. ,
Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy, N Engl J Med, vol.257, issue.11, pp.491-497, 1957. ,
Transfusions and grafts of homologous bone marrow in humans after accidental high dosage irradiation, Rev Fr Détudes Clin Biol, vol.4, issue.3, pp.226-264, 1959. ,
Identical nature of the leucocyte antigens detectable in monozygotic twins by means of immune iso-leuco-agglutinins, Nature, vol.180, issue.4599, p.1430, 1957. ,
Antileukemic effect of graft-versus-host disease in human recipients of allogeneicmarrow grafts, N Engl J Med, vol.300, pp.1068-73, 1979. ,
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients, Blood, vol.76, issue.12, pp.2462-2467, 1990. ,
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy, Blood, vol.89, issue.12, pp.4531-4537, 1997. ,
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases, Blood, vol.91, issue.3, pp.756-63, 1998. ,
Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia, Haematologica, vol.92, issue.4, pp.533-574, 2007. ,
Leucémie aiguë myéloblastique. Hématologie, vol.19, pp.30-31, 2013. ,
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.24, pp.5675-87, 2005. ,
Approche séquentielle associant une chimiothérapie par ThiotepaEtoposide-Cyclophosphamide suivie d'un conditionnement d'intensité réduite et une allogreffe de cellules souches hématopoïétiques dans le traitement des hémopathies malignes réfractaires. ROUEN, 2015. ,
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.18, issue.9, pp.1415-1436, 2012. ,
HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM, Leukemia, vol.29, issue.7, pp.1496-501, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02123041
Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.20, issue.9, pp.1349-55, 2014. ,
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, issue.36, pp.4533-4573, 2012. ,
Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS, Bone Marrow Transplant, vol.48, issue.10, pp.1296-301, 2013. ,
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes, Blood, vol.108, issue.3, pp.836-882, 2006. ,
Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia, Ann Hematol, vol.92, issue.10, pp.1397-403, 2013. ,
FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission, Eur J Haematol, vol.96, issue.5, pp.475-82, 2016. ,
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.18, issue.3, pp.466-72, 2012. ,